{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:38:13Z","timestamp":1793813893476,"version":"4.6.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cluster headache is a severe and disabling primary headache disorder. Galcanezumab is a monoclonal antibody against calcitonin gene-related peptide and a preventive therapy for episodic cluster headache. However, the approval and insurance coverage for episodic cluster headache differ in each country. Additionally, the consistency of efficacy of galcanezumab therapy has not yet been evaluated. This study aimed to assess the efficacy and safety of 240\u00a0mg of galcanezumab therapy for consecutive cluster bouts in patients with episodic cluster headache.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study enrolled patients with episodic cluster headache who received two courses of galcanezumab therapy at three university hospitals in Republic of Korea between February 2020 and April 2022. The efficacy and safety of galcanezumab were analyzed by comparing daily headache frequency, the number of headache days, and headache intensity and adverse effects during the one-week period before and the third week after galcanezumab injection for each episode of cluster bouts. Paired t-test was used for comparing repeated data from different episodes of cluster bout.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixteen patients were enrolled in this study. Fourteen patients received galcanezumab therapy for two consecutive cluster bouts. Galcanezumab was administered 24\u00a0days and 11\u00a0days after the first and second cluster bouts, respectively. The proportion of patients with 50% or more reduction in frequency of daily headache at week 3 from baseline was 86% and 64% during the first and second episodes, respectively. The proportion of patients who received transitional therapy before galcanezumab therapy was higher in the first episode of cluster bout than that in the second episode of cluster bout. No serious adverse reactions or significant differences in adverse effects between cluster bouts were noticed. Two patients received a second galcanezumab therapy during the pre-cluster period, and their cluster periods ended without typical cluster headache attacks 10\u201360\u00a0days after galcanezumab therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This exploratory analysis suggests that galcanezumab may be effective as a preventive therapy in subsequent cluster bouts. Patients with episodic cluster headaches who underwent galcanezumab therapy tended to receive a second round of treatment in the early stages of their next cluster bout without transitional therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-023-01661-7","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T14:02:36Z","timestamp":1696946556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Preventive therapy with galcanezumab for two consecutive cluster bouts in patients with episodic cluster headache: an observational multicenter study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8693-2831","authenticated-orcid":false,"given":"Yooha","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7260-3984","authenticated-orcid":false,"given":"Mi-Kyoung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6847-497X","authenticated-orcid":false,"given":"Heui-Soo","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1053-4682","authenticated-orcid":false,"given":"Byung-Kun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4053-3763","authenticated-orcid":false,"given":"Soo-Jin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"issue":"1","key":"1661_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1474-4422(17)30405-2","volume":"17","author":"J Hoffmann","year":"2018","unstructured":"Hoffmann J, May A (2018) Diagnosis, pathophysiology, and management of cluster headache. Lancet Neurol 17(1):75\u201383. https:\/\/doi.org\/10.1016\/S1474-4422(17)30405-2","journal-title":"Lancet Neurol"},{"issue":"1","key":"1661_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/head.14021","volume":"61","author":"MJ Burish","year":"2021","unstructured":"Burish MJ, Pearson SM, Shapiro RE, Zhang W, Schor LI (2021) Cluster headache is one of the most intensely painful human conditions: results from the international cluster headache questionnaire. Headache 61(1):117\u2013124. https:\/\/doi.org\/10.1111\/head.14021","journal-title":"Headache"},{"issue":"1","key":"1661_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1526-4610.2011.02028.x","volume":"52","author":"TD Rozen","year":"2012","unstructured":"Rozen TD, Fishman RS (2012) Cluster headache in the United States of America: demographics, clinical characteristics, triggers, suicidality, and personal burden. Headache 52(1):99\u2013113. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.02028.x","journal-title":"Headache"},{"key":"1661_CR4","doi-asserted-by":"publisher","unstructured":"May A, Evers S, Goadsby PJ, Leone M, Manzoni GC, Pascual J, Carvalho V, Romoli M, Aleksovska K, Pozo\u2010Rosich P (2023) European Academy of Neurology guidelines on the treatment of cluster headache. Eur J Neurol.\u00a0Advanced online publication.\u00a0https:\/\/doi.org\/10.1111\/ene.15956.","DOI":"10.1111\/ene.15956"},{"issue":"2","key":"1661_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa1813440","volume":"381","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Dodick DW, Leone M, Bardos JN, Oakes TM, Millen BA, Zhou C, Dowsett SA, Aurora SK, Ahn AH (2019) Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med 381(2):132\u2013141","journal-title":"N Engl J Med"},{"key":"1661_CR6","doi-asserted-by":"publisher","first-page":"e059577","DOI":"10.1136\/bmj-2020-059577","volume":"376","author":"EAD Schindler","year":"2022","unstructured":"Schindler EAD, Burish MJ (2022) Recent advances in the diagnosis and management of cluster headache. BMJ 376:e059577. https:\/\/doi.org\/10.1136\/bmj-2020-059577","journal-title":"BMJ"},{"issue":"1","key":"1661_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s10194-022-01505-w","volume":"23","author":"H Mo","year":"2022","unstructured":"Mo H, Kim BK, Moon HS, Cho SJ (2022) Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache. J Headache Pain 23(1):132. https:\/\/doi.org\/10.1186\/s10194-022-01505-w","journal-title":"J Headache Pain"},{"issue":"10","key":"1661_CR8","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/head.14404","volume":"62","author":"JA Membrilla","year":"2022","unstructured":"Membrilla JA, Torres-Ferrus M, Alpuente A, Caronna E, Pozo-Rosich P (2022) Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: case series and narrative review. Headache 62(10):1395\u20131405. https:\/\/doi.org\/10.1111\/head.14404","journal-title":"Headache"},{"issue":"1","key":"1661_CR9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10072-021-05624-1","volume":"43","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, Fattori D, Geppetti P, De Cesaris F (2022) Galcanezumab effectiveness on comorbid cluster headache and chronic migraine: a prospective case series. Neurol Sci 43(1):697\u2013703. https:\/\/doi.org\/10.1007\/s10072-021-05624-1","journal-title":"Neurol Sci"},{"issue":"1","key":"1661_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/neurolint15010020","volume":"15","author":"K Kashiwagi","year":"2023","unstructured":"Kashiwagi K, Katsuki M, Kawamura S, Tachikawa S, Ono A, Koh A (2023) Fremanezumab and non-high-dose galcanezumab for comorbid cluster headache in patients with migraine: three cases. Neurol Int 15(1):318\u2013324. https:\/\/doi.org\/10.3390\/neurolint15010020","journal-title":"Neurol Int"},{"issue":"14","key":"1661_CR11","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1177\/0333102420949866","volume":"40","author":"R Ruscheweyh","year":"2020","unstructured":"Ruscheweyh R, Broessner G, Gossrau G, Heinze-Kuhn K, Jurgens TP, Kaltseis K, Kamm K, Peikert A, Raffaelli B, Rimmele F, Evers S (2020) Effect of calcitonin gene-related peptide (-receptor) antibodies in chronic cluster headache: results from a retrospective case series support individual treatment attempts. Cephalalgia 40(14):1574\u20131584. https:\/\/doi.org\/10.1177\/0333102420949866","journal-title":"Cephalalgia"},{"issue":"11\u201312","key":"1661_CR12","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1177\/03331024221103509","volume":"42","author":"R Riesenberg","year":"2022","unstructured":"Riesenberg R, Gaul C, Stroud CE, Dong Y, Bangs ME, Wenzel R, Martinez JM, Oakes TM (2022) Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache. Cephalalgia 42(11\u201312):1225\u20131235. https:\/\/doi.org\/10.1177\/03331024221103509","journal-title":"Cephalalgia"},{"key":"1661_CR13","doi-asserted-by":"publisher","unstructured":"Headache classification committee of the International Headache Society (IHS) the international classification of headache disorders, 3rd edition. (2018) Cephalalgia 38 (1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"issue":"4","key":"1661_CR14","first-page":"205","volume":"18","author":"P Torelli","year":"2003","unstructured":"Torelli P, Manzoni GC (2003) Pain and behaviour in cluster headache. A prospective study and review of the literature. Funct Neurol 18(4):205\u2013210","journal-title":"Funct Neurol"},{"issue":"7","key":"1661_CR15","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1177\/03331024211067784","volume":"42","author":"S Cho","year":"2022","unstructured":"Cho S, Cho S-J, Lee MJ, Park JW, Chu MK, Moon H-S, Chung P-W, Sohn J-H, Kim B-S, Kim D (2022) Characteristics of pre-cluster symptoms in cluster headache: a cross-sectional multicentre study. Cephalalgia 42(7):570\u2013578","journal-title":"Cephalalgia"},{"issue":"2","key":"1661_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1046\/j.1468-2982.1998.1802091.x","volume":"18","author":"J Blau","year":"1998","unstructured":"Blau J, Engel H (1998) Premonitory and prodromal symptoms in cluster headache. Cephalalgia 18(2):91\u201393","journal-title":"Cephalalgia"},{"issue":"2","key":"1661_CR17","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/00006842-200203000-00008","volume":"64","author":"K Kroenke","year":"2002","unstructured":"Kroenke K, Spitzer RL, Williams JB (2002) The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 64(2):258\u2013266","journal-title":"Psychosom Med"},{"issue":"4","key":"1661_CR18","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.1526-4610.2011.02024.x","volume":"52","author":"MS Robbins","year":"2012","unstructured":"Robbins MS, Bronheim R, Lipton RB, Grosberg BM, Vollbracht S, Sheftell FD, Buse DC (2012) Depression and anxiety in episodic and chronic cluster headache: a pilot study. Headache 52(4):600\u2013611","journal-title":"Headache"},{"issue":"8","key":"1661_CR19","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/j.1524-4733.2009.00579.x","volume":"12","author":"YK Lee","year":"2009","unstructured":"Lee YK, Nam HS, Chuang LH, Kim KY, Yang HK, Kwon IS, Kind P, Kweon SS, Kim YT (2009) South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states. Value in health 12(8):1187\u20131193","journal-title":"Value in health"},{"issue":"7","key":"1661_CR20","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD (2007) The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 4(7):28","journal-title":"Psychiatry (Edgmont)"},{"issue":"7","key":"1661_CR21","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1177\/0333102421989255","volume":"41","author":"AS Pedersen","year":"2021","unstructured":"Pedersen AS, Snoer A, Barloese M, Petersen A, Jensen RH (2021) Prevalence of pre-cluster symptoms in episodic cluster headache: Is it possible to predict an upcoming bout? Cephalalgia 41(7):799\u2013809","journal-title":"Cephalalgia"},{"key":"1661_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40263-019-00696-2","volume":"34","author":"RB Brandt","year":"2020","unstructured":"Brandt RB, Doesborg PG, Haan J, Ferrari MD, Fronczek R (2020) Pharmacotherapy for cluster headache. CNS Drugs 34:171\u2013184","journal-title":"CNS Drugs"},{"issue":"3","key":"1661_CR23","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/0333102417741297","volume":"39","author":"S Khan","year":"2019","unstructured":"Khan S, Olesen A, Ashina M (2019) CGRP, a target for preventive therapy in migraine and cluster headache: systematic review of clinical data. Cephalalgia 39(3):374\u2013389","journal-title":"Cephalalgia"},{"issue":"10","key":"1661_CR24","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1111\/head.14011","volume":"60","author":"D Kudrow","year":"2020","unstructured":"Kudrow D, Andrews JS, Rettiganti M, Oakes T, Bardos J, Gaul C, Riesenberg R, Wenzel R, Kuruppu D, Martinez J (2020) Treatment outcomes in patients treated with galcanezumab vs placebo: post hoc analyses from a phase 3 randomized study in patients with episodic cluster headache. Headache 60(10):2254\u20132264. https:\/\/doi.org\/10.1111\/head.14011","journal-title":"Headache"},{"issue":"1","key":"1661_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12883-020-1609-7","volume":"20","author":"ME Bangs","year":"2020","unstructured":"Bangs ME, Kudrow D, Wang S, Oakes TM, Terwindt GM, Magis D, Yunes-Medina L, Stauffer VL (2020) Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. BMC Neurol 20(1):25. https:\/\/doi.org\/10.1186\/s12883-020-1609-7","journal-title":"BMC Neurol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01661-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01661-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01661-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T06:02:34Z","timestamp":1700373754000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01661-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1661"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01661-7","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"assertion":[{"value":"26 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocols for the prospective and retrospective registries were approved by the institutional review board (IRB) of each hospital (EMCS 2021\u201310\u2013032\u2013001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consented.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"136"}}